Please type a plus (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Attorney Docket No. Total Pages 10412-022 UTILITY First Named Inventor or Application Identifier PATENT APPLICATION Robert E. KLEM TRANSMITTAL Express Mail Label No. (Only for new nonprovisional applications under 37 CFR 1.53(b)) EL 477 034 015 US Assistant Commissioner for Patents APPLICATION ELEMENTS
See MPEP chapter 600 concerning utility patent application contents. ADDRESS TO: Box Patent Application Washington, DC 20231 ☑ Fee Transmittal Form ☐ CD-ROM or CD-R in duplicate, large table or Computer Submit an original, and a duplicate for fee processing) Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission Applicant claims Small Entity status, see 37 C.F.R. § 1.27 (if applicable, all necessary) ☑ Specification [Total Pages 68] □ Computer Readable Copy (preferred arrangement set forth below) -Descriptive title of the Invention ☑ Paper Copy (identical to computer copy) -Cross Reference to Related Applications -Statement Regarding Fed sponsored R&D c.

Statement verifying identity of above copies -Reference to Microfiche Appendix -Background of the Invention ACCOMPANYING APPLICATION PARTS -Brief Summary of the Invention -Brief Description of the Drawings (if filed) 9. ☐ Assignment Papers (cover sheet & document(s)) -Detailed Description of the Invention (including drawings, if filed) ू -Claim(s) 10 37 CFR 3.73(b) Statement ☐ Power of Attorney -Abstract of the Disclosure (when there is an assignee) Drawing(s) (35 USC 113) [Total Sheets 1 11.

English Translation Document (if applicable) 12. Information Disclosure Statement Oath or Declaration ☐ Copies of IDS [Total Sheets 2] (IDS)/PTO-1449 Citations a ☐ ☑ Unexecuted (original or copy) 13. Preliminary Amendment b ☐ Copy from a prior application (37 CFR 1.63(d)) 14.

☐ Return Receipt Postcard (MPEP 503) (for continuation/divisional with Box 19 completed) (Should be specifically itemized) 15. ☐ Certified Copy of Priority Document(s) ☐ DELETION OF INVENTORS(S) (if foreign priority is claimed) Signed statement attached deleting inventor(s) named in the prior 16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(i). application, see 37 CFR 1.63(d)(2) and 1.33 (b). Applicant must attach form PTO/SB/35 or it's equivalent ☐ Application Data Sheet. See 37 CFR 1.76 17. 🗆 If a CONTINUING APPLICATION, check appropriate box and supply the requisite information: □ Continuation □ Divisional □ Continuation-in-part (CIP) of prior application No:

19. CORRESPONDENCE ADDRESS Customer Number: 20583 (Insert Customer No. or Attach bar code label here) or \square Correspondence address below NAME ADDRESS CITY STATE ZIP CODE COUNTRY **TELEPHONE**

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

FAX

Express Mail No.: EL 477 034 015 US

PENNIE & EDMONDS LLP

COUNSELLORS AT LAW 1155 Avenue of Americas New York, N.Y. 10036-2711

ATTORNEY DOCKET NO. 10412-022

Date: January 22, 2002

Assistant Commissioner for Patents Box PATENT APPLICATION Washington, D.C. 20231

Sir:

The following utility patent application is enclosed for filing:

Applicant(s): Robert E. KLEM

Executed on: Unexecuted

Title of Invention:

METHODS AND COMPOSITIONS FOR TREATING A CELL-PROLIFERATIVE DISORDER USING CRE DECOY OLIGOMERS, BCL-2 ANTISENSE OLIGOMERS, AND HYBRID

OLIGOMERS THEREOF

PATENT APPLICATION FEE VALUE

1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1						
TYPE	NO. FILED	LESS	EXTRA	EXTRA RATE	FEE	
Total Claims	71	-20	51	\$18.00 each	\$	918.00
Independent	6	-3	3	\$84.00 each	\$	252.00
	Minimum Fee				\$	740.00
der i der	Multiple Dependency Fee If Applicable (\$280.00) Total Applicant qualifies for the 50% Reduction for Independent Inventor, Nonprofit Organization or Small Business Concern Total Filing Fee				\$	0.00
e Table					\$	1,910.00
ulin and a second					- \$	955.00
					<u> </u>	955.00

- DO NOT PUBLISH. I hereby certify that the invention disclosed in the attached application has not and will not be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. I hereby request that the attached application not be published under 35 U.S.C. 122(b).
- Priority of application no. 60/283,244 filed on January 22, 2001 in U.S. is claimed under 35 U.S.C. § 119. \boxtimes
- The certified copy of the priority application has been filed in application no. filed
- Amend the specification by inserting before the first line the following sentence: This is a continuation-in-part of application no. filed.

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is

enclosed.

Respectfully submitted.

PENNIE & EDMONDS LLP

Laura A. Coruzzi

Enclosure

This form is not for use with continuation, divisional, re-issue, design or plant patent applications.

Express Mail No. EL 477 034 015 US

Atty Docket No.: 10412-022

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Robert E. Klem

Application No.: To be Assigned Art Unit: Not Yet Assigned

Filed: On Even Date Herewith Examiner: Not Yet Assigned

For: METHODS AND COMPOSITIONS FOR

TREATING A CELL-PROLIFERATIVE DISORDER USING CRE DECOY OLIGOMERS, BCL-2 ANTISENSE

OLIGOMERS, AND HYBRID OLIGOMERS

THEREOF

TRANSMITTAL OF SEQUENCE LISTING

Assistant Commissioner for Patents Washington, DC 20231

SIR:

In connection with the above-identified application, and in accordance with 37 C.F.R. § 1.821, Applicant submits herewith a Sequence Listing in paper and computer-readable format pursuant to 37 C.F.R. § 1.821(c) and (e).

I hereby state that the content of the paper and computer-readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same. I hereby state that the submission herein under 37 C.F.R. §1.821(g) does not include new matter.

Date January 22, 2002

Respectfully submitted,

Dy Jacqueline Bennery 2, 2002

Laura A. Coruzzi

(Reg. No.)

PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, New York 10036-2711 (212) 790-9090

Enclosures